Visit the Canadian Bioceutical Corp Investor Dashboard and stay up to date with data-driven, fact based due diligence for active traders and investors.
Civilized continued its excellent “C-Suite” series of interviews with leading cannabis industry executives, interviewing Scott Boyes, CEO of The Canadian Bioceutical Corporation (CSE: BCC) (OTC: CBICF), which is rapidly assembling a portfolio of cannabis assets across the United States. Boyes described how the company differs from others in the industry, with its ability to bring not only capital but also operational expertise. His company partners with strong operators looking for a financial partner and with new cannabis companies looking for operational know-how and access to the companies brands, Health for Life and Melting Point Extracts (MPX).
Boyes discussed the company’s current footprint in Arizona, Nevada, Massachusetts and Maryland, pointing to the limited number of licenses available in the medical-only states that allows the company the ability to grow without too much initial competition. At the same time, the Nevada and Massachusetts market opportunities are substantial given that the states are legal or in the process of legalizing for adult-use. The company’s assets, once developed fully, will be capable of producing 9mm grams of flower and processing 1.2m grams of concentrates, and BCC will be operating 10 dispensaries in four states.
Read Nick Hilden’s “”Honesty And Loyalty Are Key”: An Interview With Canadian Bioceutical CEO Scott Boyes”: https://www.civilized.life/articles/canadian-bioceutical-scott-boyes-interview/
The most reliable, fact-based information on the Canadian Bioceutical Corp found only on its Investor Dashboard.
Before this cannabis stock news is here, it's published to subscribers on 420 Investor.